Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

Healthy Volunteers Clinical Trial

Official title:

A Phase 1 Safety, Tolerability, Pharmacokinetic, Placebo-Controlled and Open-Label Study of Escalating Single and Multiple Oral Doses, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Subjects of TAK-915 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02461160
• Other study ID #: TAK-915-1001
• Secondary ID: U1111-1168-6456
• Status: Completed
• Phase: Phase 1
• Start date: May 12, 2015
• Est. completion date: August 1, 2016

Study information

• Verified date: October 2018
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize the safety, tolerability and plasma pharmacokinetic (PK) profile of TAK-915 when administered as single and multiple oral suspension doses at escalating dose levels in healthy participants, including elderly participants.

Description:

The drug being tested in this study is called TAK-915. TAK-915 is being tested to find a safe and well-tolerated dose. This study will look at the pharmacokinetic characteristics (how the drug acts throughout the body) of the drug and safety and tolerability (lab results, vital signs, ECG, and side effects) in healthy people (including elderly) who take TAK-915.

The study will enroll a total of 88 patients. This study is designed to consist of 5 different dosing schedules: single rising dose (SRD), multiple rising dose (MRD), drug-drug interaction (DDI), bioavailability and food effect (BA/FE), and Elderly Subject Single Dose (ESSD). The study population for SRD will consist of 48 participants enrolled into 6 cohorts. Each cohort will have 8 randomized participants, with 6 receiving a single dose of TAK-915, and 2 receiving matching placebo under fasted conditions. The starting dose is 30 mg. The dose for Cohorts 2 through 6 will be determined based on data collected from previous cohorts.

The study population for MRD will consist of 32 participants enrolled into 4 cohorts. Each cohort will have 8 randomized participants, with 6 receiving one dose of TAK-915 on Day 1 and daily dosing on Days 8-14, and 2 receiving matching placebo under fasted conditions. The dose for each cohort in Part 2 will be determined based on data collected from completed SRD cohorts of the study.

The study population for DDI will consist of 12 participants enrolled into 1 cohort. All participants will receive one dose of TAK-915 on Day 3 and daily dosing on Days 10-16 under fasted conditions. All participants will also receive a single dose of Midazolam 2 mg on Day 1 and Day 16. The dose of TAK-915 in this cohort will be determined based on data collected from SRD cohorts and will be the same dose that is administered in MRD Cohort 8.

The study population for BA/FE will consist of 12 participants enrolled into 1 cohort. TAK-915 will be administered in 3 single-dose regimens in a 3-way crossover design using 50 mg oral dose treatments (Regimen A: TAK915 50 mg oral suspension formulation in fasted state; Regimen B: TAK-915 50 tablet formulation in fasted state; Regimen C: TAK-915 50 tablet formulation in fasted state). TAK-915 dosing will occur on Day 1 of each treatment period followed by a 14 day washout period.

The study population for ESSD will consist of 8 elderly participants (ages 65-75 years) enrolled into 1 cohort. All 8 participants will receive a single dose of TAK-915 50 mg suspension under fasted conditions.

This single-center trial will be conducted in the United States. The overall time to participate in this study is up to 70 days. Participants will make multiple visits to the clinic including a period of confinement to the clinic and will be contacted by telephone 12 days after the last dose of study drug for a follow-up assessment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 88
• Est. completion date: August 1, 2016
• Est. primary completion date: August 1, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.

2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures including requesting that a participant fast for any laboratory evaluations.

3. Is a healthy man or woman, aged 18 to 55 years, inclusive at the time of informed consent and first study medication dose for all cohorts will be included. Note that Cohort 12 will enroll healthy, elderly men and women, aged 65 to 75 years, inclusive.

4. Weighs at least 50 kg and has a body mass index (BMI) from 18.0 to 35.0 kg/m^2, inclusive at Screening.

5. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last dose.

6. A female participant with no childbearing potential, defined as the participant has been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation) or who are postmenopausal (defined as continuous amenorrhea of at least 2 y ears and follicle stimulating hormone (FSH) >40 IU/L).

Exclusion Criteria:

1. Has received any investigational compound within 30 days prior to the first dose of study medication.

2. Has received TAK-915 in a previous clinical study or as a therapeutic agent.

3. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.

4. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, or psychiatric disorder, or other abnormality, which may impact the ability of the participant to participate or potentially confound the study results.

5. Has a known hypersensitivity to any component of the formulation of TAK-915 and/or midazolam.

6. If female, the participant is of childbearing potential (eg. premenopausal, not sterilized).

7. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day 1).

8. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening Visit or is unwilling to agree to abstain from alcohol and drugs throughout the study. One unit is equivalent to a half-pint of beer or 1 measure of spirits or 1 glass of wine.

9. Has taken any excluded medication, supplements, or food products during the time periods listed in the Excluded Medications and Dietary Products table.

10. Is pregnant or lactating or intending to become pregnant before, during, or within 12 weeks after participating in this study ; or intending to donate ova during such time period.

11. If male, the participant intends to donate sperm during the course of this study or for 12 weeks after the last dose of study medication.

12. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding in the participant's medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking TAK-915, or a similar drug in the same class, or that might interfere with the conduct of the study. This includes, but is not limited to, peptic ulcer disease, seizure disorders, and cardiac arrhythmias.

13. Has mental retardation or medical condition that can cause cognitive impairment.

14. Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (ie, a history of malabsorption, any surgical intervention known to impact absorption [eg, bariatric surgery or bowel resection], esophageal reflux, peptic ulcer disease, erosive esophagitis, or frequent [more than once per week] occurrence of heartburn).

15. Has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Check-in (Day -1).

16. Has a positive test result for hepatitis B surface antigen (HBsAg), antibody to hepatitis C (anti -HCV) or a known history of human immunodeficiency virus infection at Screening.

17. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, electronic cigarettes, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in (Day -1). Cotinine test is positive at Screening or Check-in (Day -1).

18. Has donated or lost 450 mL or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days prior the first dose of study medication.

19. Has a Screening or Check-in (Day -1) abnormal (clinically significant) electrocardiogram (ECG). Entry of any participant with an abnormal (not clinically significant) ECG must be approved and documented by signature by the principal investigator.

20. Has a supine blood pressure outside the ranges of 90 to 140 mmHg for systolic and 60 to 90 mmHg for diastolic, confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in (Day -1).

21. Has a resting heart rate outside the range 40 to 100 bpm, confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in (Day -1).

22. Has a QT interval with Fridericia correction method (QTcF) >430 ms (males) or >450 ms (females) or PR outside the range 120 to 220 ms, confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in (Day -1).

23. Has abnormal Screening or Check-in (Day -1) laboratory values that suggest a clinically significant underlying disease or participant with the following lab abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5 the upper limits of normal.

24. Has a risk of suicide according to the Investigator's clinical judgment (eg, per Columbia-Suicide Severity Rating Scale [C-SSRS] or has made a suicide attempt in the previous 6 months).

25. Has poor peripheral venous access.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• TAK-915 suspension
TAK-915 oral suspension
• Midazolam
Midazolam oral solution
• Placebo
Placebo-matching TAK-915 suspension
• TAK-915 tablet
TAK-915 tablet

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)	An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.	Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)
Primary	Percentage of Participants With Markedly Abnormal Safety Laboratory Tests	The percentage of participants with any markedly abnormal standard safety laboratory values, including haematology, serum chemistries, or urinalysis, during the treatment period.	Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)
Primary	Percentage of Participants With Markedly Abnormal Vital Sign Measurements	The percentage of participants who meet markedly abnormal criteria for vital signs after dosing, including oral body temperature (temp.), respiration rate, pulse rate (PR) Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) for assessment in positions of supine or standing. Vital signs were considered abnormal if they were beyond the values defined in categories.	Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)
Primary	Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters	The percentage of participants who meet markedly abnormal criteria for ECG parameters as specified by the protocol and statistical analysis plan during the treatment period. ECG parameters were considered abnormal if they were beyond the values defined in categories.	Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)
Primary	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915		SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Primary	Cmax: Maximum Observed Plasma Concentration for TAK-915		SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Primary	AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915		SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Primary	AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915		SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Primary	AUC8: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915		Day 1 pre-dose and at multiple time points (up to 96 hours) post dose
Primary	Rac(AUC): Accumulation Ratios Between Day 14 AUC(0-24) and Day 1 AUC(0-24) for TAK-915		Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose
Primary	Rac(Cmax): Accumulation Ratios Between Day 14 Cmax and Day 1 Cmax for TAK-915		Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose
Primary	Time Dependency Assessment From AUC(0-24) After Last Dose for TAK-915 on Day 14 in MRD Cohorts Compared to AUC(0-inf) After a Single Dose on Day 1		Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose
Primary	Cmax: Maximum Observed Plasma Concentration for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort		Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose
Primary	AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort		Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose
Primary	AUC(0-24) for Midazolam After Single Dose (Day 1)/AUC(0-24) for Midazolam After 7 Daily Doses of TAK-915 (Day 16) in DDI Cohort		Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose
Secondary	Terminal Elimination Half-life (t1/2) for TAK-915		SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Secondary	CL/F: Apparent Clearance for TAK-915		SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Secondary	Apparent Volume of Distribution (Vz/F) for TAK-915		SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Secondary	Total Amount of Drug Excreted in Urine (Ae) for TAK-915		SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Secondary	Fraction of Drug Excreted in Urine (Fe) for TAK-915		SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Secondary	Renal Clearance (CLr) for TAK-915		SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose
Secondary	Cmax: Maximum Observed Plasma Concentration for TAK-915 on Day 1 in DDI Cohort		Days 1 at multiple time points (up to 96 hours) post dose
Secondary	AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915 on Day 1 in DDI Cohort		Days 1 at multiple time points (up to 96 hours) post dose
Secondary	AUC(0-tau): Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval Where Tau is the Length of the Dosing Interval for TAK-915 in DDI Cohort		Days 16 at multiple time points (up to 96 hours) post dose
Secondary	Ratio of TAK-915 Metabolite Cmax to TAK-915 Cmax in SRD and MRD Cohorts		Day 1 predose and at multiple time points (up to 96 hours) post-dose
Secondary	Ratio of TAK-915 Metabolite AUC(0-inf) to TAK-915 AUC(0-inf) in SRD Cohorts		Day 1 predose and at multiple time points (up to 96 hours) post-dose
Secondary	Ratio of TAK-915 Metabolite Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval [AUC(0-tau)] Where Tau is the Length of the Dosing Interval to TAK-915 AUC(0-tau) in MRD Cohorts		Day 14 predose and at multiple time points (up to 96 hours) post-dose
Secondary	Cmax: Maximum Observed Plasma Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort		Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose
Secondary	AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort		Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose
Secondary	AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort		Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose
Secondary	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort		Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose
Secondary	Terminal Elimination Half-life (t1/2) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort		Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose
Secondary	?z: Terminal Elimination Rate Constant for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort		Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose